Mr. McGorry has more than 25 years of experience as a life science business leader in biologics, personalized medicine and medical devices, including multiple product launches. He also has been a member of the HART Board of Directors since 2/13.
Mr. McGorry most recently served as EVP and General Manager, Translational Oncology Solutions for Champions Oncology and previously was EVP of Commercial Operations at Accellent.
During his 12-year tenure at Genzyme, he held leadership positions across several therapeutic areas, including Bio Surgery, Cardiac Surgery, Oncology and Transplant. Mr. McGorry also was President of Clineffect Systems, an electronic medical records company. He began his life sciences career with Baxter, where he spent 11 years in positions of increasing responsibility.
Mr. McGorry has an MBA with a concentration in healthcare from Duke University, Fuqua School of Business and a B.S. in engineering from the United States Military Academy at West Point where he was the president of his class. Mr. McGorry also served as an officer in the US Army for six years, including commanding a special operations Green Beret SCUBA detachment.
There all about protecting what they have without projecting what the should be doing about cost inefficiencies, overhead, burn, corporate comp and facilitating their "own" agendas - look at the ... too far away Basking Ridge office at 106 Allen Street from HQ in NYC where almost all employees are located. . Does the bank account reflect an input of $17.7 m from CIRM - NO, it is overtime based on milestone and 40/60 matching for each dollar spent. Management should be more specific re the truths of the status. The most recent offering was just a ... vehicle for the shorts to "cover". And, then look at the blossoming usage of the ATM - still debt with a sliding time factor ... into the daily/weekly/monthly market ...affecting the share pricing